SEC Filing Summary: ChromaDex Corporation (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ChromaDex Corporation on March 11, 2016. The filing discloses the entry into a Material Definitive Agreement and the unregistered sale of equity securities. Note: The input metadata references "Niagen Bioscience, Inc.," but the filing text explicitly identifies the registrant as ChromaDex Corporation.
Key Financial Metrics and Transaction Details
The Company completed a registered direct offering with the following terms:
- Units Sold: 384,615 Units
- Purchase Price: $1.30 per Unit
- Gross Proceeds: Approximately $500,000 (calculated as 384,615 units x $1.30)
- Unit Composition: One share of Common Stock and one Warrant to purchase 0.5 shares of Common Stock.
- Warrant Terms: Exercise price of $1.60 per share; exercisable immediately; expires three years from issuance.
- Underwriting: No underwriter or placement agent was engaged.
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity metrics as this is a transactional report rather than a periodic financial statement.
Material Changes and Unusual Items
The primary material change is the dilution of existing shareholders due to the issuance of 384,615 new shares of Common Stock and the creation of warrants for an additional 192,307.5 potential shares. The Warrants are subject to a beneficial ownership limitation, prohibiting exercise if the holder would own more than 4.99% of the outstanding Common Stock immediately after exercise.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond standard legal disclaimers. The Warrants and Warrant Shares were sold pursuant to an exemption from registration under Section 4(2) of the Securities Act and/or Regulation D to an accredited investor.
Investor Verification Checklist
- Verify the total number of shares outstanding post-transaction to assess dilution impact.
- Confirm the use of proceeds from the $500,000 offering in subsequent filings (e.g., 10-Q or 10-K).
- Review the full text of the Securities Purchase Agreement (Exhibit 10.01) and Warrant (Exhibit 10.02) for specific covenants and redemption rights.
- Monitor future filings for any exercise of the warrants issued in this transaction.